The dyslipidemia of chronic renal disease: effects of statin therapy

Related Experiment Video

Updated: Jul 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Riza C Ozsoy1, Sander I van Leuven, John J P Kastelein

  • 1Department of Nephrology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Current Opinion in Lipidology
|November 11, 2006
PubMed

Insights

Early screening for dyslipidemia in chronic renal disease patients is crucial. Statin therapy effectively lowers cardiovascular risk and may offer renoprotective benefits, but benefits are limited if initiated late.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Dyslipidemia is common in chronic renal disease (CRD) but frequently undertreated.
  • Lipid abnormalities in CRD are linked to proteinuria and reduced creatinine clearance, potentially worsening kidney disease progression.
  • Cardiovascular disease is a major cause of mortality in CRD patients.

Purpose of the Study:

  • To review current research on dyslipidemia in CRD patients.
  • To summarize the efficacy and potential benefits of statin treatment for dyslipidemia in CRD.
  • To highlight the importance of early intervention with statins.

Main Methods:

  • Review of existing studies on dyslipidemia and statin therapy in chronic renal disease.
  • Analysis of data from large-scale lipid-lowering trials, including post-hoc analyses.
  • Evaluation of both lipid-lowering and pleiotropic effects of statins.

Main Results:

  • Statin therapy can improve lipid profiles in CRD patients.
  • Statins demonstrate renoprotective effects through lipid reduction, anti-inflammatory actions, and decreased proteinuria.
  • Cardiovascular risk reduction with statins in CRD patients is comparable to that in patients without renal failure.

Conclusions:

  • Early screening for dyslipidemia in CRD patients is recommended.
  • Statins are the preferred lipid-lowering therapy, reducing cardiovascular risk.
  • Further research is needed to confirm the renal function-preserving effects of statins.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...